
A $2 billion entered in favor of a Livermore, California couple that had contracted non-Hodgkin’s lymphoma because of their use of Round-Up Weed Killer produced by Monsanto. Monsanto is appealing the verdict.
The root of the legal issue revolves around the key ingredient in Roundup, glyphosate. Bayer maintained that glyphosate is not a carcinogen, but plaintiffs offer research that shows glyphosate can cause non-Hodgkin’s lymphoma and multiple myeloma. Glyphosate is the most widely-used herbicide in the United States. It is used on nearly every acre of corn, cotton, and soybeans grown in the United States and many Americans have used it to treat their lawns and gardens. Despite its common use, many jurisdictions across the country have banned or restricted the use of glyphosate until more is known about its health effects.
Roundup was first sold commercially by Monsanto in 1974, but Monsanto genetically engineered crops to tolerate glyphosate in 1996, which became known as “Roundup Ready” seeds, that furthered Roundup’s use on farms across the globe. Due to its widespread use, glyphosate can be found in water, food, and dust. However, little is known about the magnitude of human exposure because of minimal testing for glyphosate residue. While Bayer maintains that the active agent in Roundup does not pose a risk to people and the Environmental Protection Agency decided that it did “not likely” cause cancer in humans, the World Health Organization’s International Agency for Research on Cancer called glyphosate a “probable human carcinogen.”
Chicago Accident Lawyer Blog






